tci Part B Insider - 2005 Issue 17

PHYSICIAN NOTES: CMS Will Expand Coverage Of Abarelix For Prostate Cancer

And at least one carrier will now pay for Abraxane for breast cancer If you've been providing abarelix (brand name Plenaxis) for advanced symptomatic prostate cancer, then there's good news from the Centers for Medicare and Medicaid Services. Transmittal 532 states that Medicare will expand coverage for Plenaxis to include patients for whom gonadotropin-releasing hormone (GnRH) therapy is not appropriate, who decline surgical castration, and who present with risk of neurological compromise due to metastases, ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or severe bone pain from skeletal metastases persisting on narcotic analgesia. In...

To read the full article, sign in and subscribe to tci Part B Insider.


Keep pace with evolving Medicare regulations with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI’s Part B Insider will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, the fee schedule, OIG target areas, and more.

  • Current newsletters added each month
  • Fully searchable archives - over 4800 articles
  • ALL years/issues back to 2003 organized by year and issue
  • Codes mentioned in articles are linked to Code Information pages
  • Code Information pages link back to related articles

This feature is currently unavailable for online purchase. For more information, please call 801-770-4203 or Contact Us.

demo
request yours today
subscribe
start today
newsletter
free subscription

Thank you for choosing Find-A-Code, please Sign In to remove ads.